Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.

Dean Fennell

Research output: Contribution to journalArticle

77 Citations (Scopus)
Original languageEnglish
Pages (from-to)5942-5951
Number of pages10
JournalClinical Cancer Research
Issue number19
Publication statusPublished - 01 Oct 2007

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this